JMP Securities Reiterates Market Outperform on Halozyme Therapeutics, Maintains $72 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jason Butler has reiterated a 'Market Outperform' rating on Halozyme Therapeutics (NASDAQ:HALO) and maintained a price target of $72.
February 21, 2024 | 5:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities reaffirms a 'Market Outperform' rating on Halozyme Therapeutics with a $72 price target.
The reiteration of a 'Market Outperform' rating and the maintenance of a $72 price target by JMP Securities indicates a strong analyst confidence in Halozyme Therapeutics. This positive outlook is likely to influence investor sentiment positively in the short term, potentially leading to an increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100